Soleil Boughton Sells 2,339 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the sale, the insider now owns 176,952 shares of the company’s stock, valued at $2,919,708. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, September 3rd, Soleil Boughton sold 2,345 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.65, for a total transaction of $34,354.25.
• On Tuesday, August 6th, Soleil Boughton sold 2,334 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.30, for a total value of $40,378.20.
• On Tuesday, July 23rd, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.29, for a total value of $47,377.15.
• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.28, for a total value of $47,353.80.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $0.18 on Tuesday, reaching $16.10. The company’s stock had a trading volume of 5,079,143 shares, compared to its average volume of 7,771,740. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The firm’s 50 day moving average is $17.62 and its two-hundred day moving average is $17.05. The stock has a market cap of $3.46 billion, a PE ratio of -1,610.00 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) earnings per share. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on HIMS shares. Needham & Company LLC began coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. TD Cowen raised their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group increased their price target on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.86.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the company. Arizona State Retirement System boosted its position in Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after purchasing an additional 1,173 shares during the period. Belpointe Asset Management LLC grew its holdings in Hims & Hers Health by 10.0% in the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock valued at $393,000 after acquiring an additional 1,212 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Finally, Swiss National Bank increased its position in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after acquiring an additional 2,000 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.